Nalaganje...
Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report
BACKGROUND: Trastuzumab (T-mab)-based chemotherapy is a standard regimen for human epithelial growth factor 2 (HER2)-positive gastric cancer. However, some patients have demonstrated a change in HER2 status after T-mab-based treatment of breast cancer. We report a rare case of mixed adenoneuroendocr...
Shranjeno v:
| izdano v: | Surg Case Rep |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Berlin Heidelberg
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6949340/ https://ncbi.nlm.nih.gov/pubmed/31916037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40792-020-0774-7 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|